Indian pharmaceutical company Lupin Limited has appointed Spiro Gavaris as president of its US generics business.

Spiro Gavaris, who will be a part of the senior leadership team of the company, will handle the overall strategy, implementation, and expansion of the American generics business in the US.

According to Lupin, Spiro Gavaris joins the company with considerable experience in the branded, biotech, and generic industries. Most recently, he was Mallinckrodt Pharmaceuticals president of specialty generics business and Hikma president of US injectables.

Vinita Gupta — Lupin CEO said: “Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front.

  Lupin, Spiro Gavaris, USA, Vinita Gupta